BioMarin Pharmaceutical Inc. (0HNC.L)
| Previous close | 79.40 |
| Open | 78.32 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 78.32 - 78.32 |
| 52-week range | 78.32 - 78.32 |
| Volume | 5 |
| Avg. volume | N/A |
| Market cap | 14.263B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | 17.31 |
| EPS (TTM) | 4.53 |
| Earnings date | 27 Apr 2021 - 03 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- IPO-Edge.com
Replay: Investing in Alzheimer’s Treatment — Jupiter Orphan Therapeutics CEO Joins Fireside Chat
Christer Rosén, Chairman-CEO & Founder of Jupiter Orphan Therapeutics, Inc, Raymond “Scott” Turner MD, Professor Neurology, Georgetown University (Alzheimer’s scientist) and Mark Dant, Executive Director, Ryan Foundation IPO Edge, in partnership with The Palm Beach Hedge Fund Association, a Florida trade association for financial professionals and ultra high net worth investors, hosted a fireside chat Tuesday, […]
- Zacks
BioMarin (BMRN) Down 7.7% Since Last Earnings Report: Can It Rebound?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- IPO-Edge.com
Investing in Alzheimer’s Treatment: Join Jupiter Orphan Therapeutics for Fireside Chat March 30
Christer Rosén, Chairman-CEO & Founder of Jupiter Orphan Therapeutics, Inc, Raymond “Scott” Turner MD, Professor Neurology, Georgetown University (Alzheimer’s scientist) and Mark Dant, Executive Director, Ryan Foundation IPO Edge, in partnership with The Palm Beach Hedge Fund Association, a Florida trade association for financial professionals and ultra high net worth investors, will host a fireside chat […]
